You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

VERSED Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Versed, and when can generic versions of Versed launch?

Versed is a drug marketed by HLR and Roche and is included in two NDAs.

The generic ingredient in VERSED is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Versed

A generic version of VERSED was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.

  Try a Trial

Drug patent expirations by year for VERSED
Recent Clinical Trials for VERSED

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lawson Health Research InstitutePhase 3
University of Texas Southwestern Medical CenterPhase 3
National Institute of Mental Health (NIMH)Phase 3

See all VERSED clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for VERSED

US Patents and Regulatory Information for VERSED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-002 May 26, 1987 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-001 Dec 20, 1985 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Roche VERSED midazolam hydrochloride SYRUP;ORAL 020942-001 Oct 15, 1998 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VERSED

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-002 May 26, 1987 ⤷  Try a Trial ⤷  Try a Trial
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-001 Dec 20, 1985 ⤷  Try a Trial ⤷  Try a Trial
Roche VERSED midazolam hydrochloride SYRUP;ORAL 020942-001 Oct 15, 1998 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VERSED

See the table below for patents covering VERSED around the world.

Country Patent Number Title Estimated Expiration
South Africa 7505418 ⤷  Try a Trial
Canada 1076572 DERIVES DE LA DIAZEPINE (DIAZEPINE DERIVATIVES) ⤷  Try a Trial
Portugal 64882 DERIVES DE DIAZEPINE ⤷  Try a Trial
Yugoslavia 40267 ⤷  Try a Trial
Norway 802651 ⤷  Try a Trial
Sweden 445918 DIAZEPINDERIVAT TILL ANVENDNING SOM MELLANPRODUKTER ⤷  Try a Trial
Norway 149136 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.